CN101810818B - Chinese medicinal composition for treating duodenal ulcer and preparation method thereof - Google Patents
Chinese medicinal composition for treating duodenal ulcer and preparation method thereof Download PDFInfo
- Publication number
- CN101810818B CN101810818B CN2010101430225A CN201010143022A CN101810818B CN 101810818 B CN101810818 B CN 101810818B CN 2010101430225 A CN2010101430225 A CN 2010101430225A CN 201010143022 A CN201010143022 A CN 201010143022A CN 101810818 B CN101810818 B CN 101810818B
- Authority
- CN
- China
- Prior art keywords
- ulcer
- extract
- percent
- weight ratio
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 77
- 208000000718 duodenal ulcer Diseases 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title abstract description 6
- 244000044425 Quisqualis indica Species 0.000 claims abstract description 6
- 239000000654 additive Substances 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 81
- 239000009636 Huang Qi Substances 0.000 claims description 5
- 244000294611 Punica granatum Species 0.000 claims description 5
- 235000014360 Punica granatum Nutrition 0.000 claims description 5
- 230000000996 additive effect Effects 0.000 claims description 3
- 238000003809 water extraction Methods 0.000 claims 1
- 239000000284 extract Substances 0.000 abstract description 21
- 235000013399 edible fruits Nutrition 0.000 abstract description 8
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 244000202052 Poncirus trifoliata Species 0.000 abstract description 2
- 235000000404 Poncirus trifoliata Nutrition 0.000 abstract description 2
- 241001313855 Bletilla Species 0.000 abstract 1
- 235000002991 Coptis groenlandica Nutrition 0.000 abstract 1
- 244000247747 Coptis groenlandica Species 0.000 abstract 1
- 241001673966 Magnolia officinalis Species 0.000 abstract 1
- 235000010575 Pueraria lobata Nutrition 0.000 abstract 1
- 244000046146 Pueraria lobata Species 0.000 abstract 1
- 235000019206 astragalus extract Nutrition 0.000 abstract 1
- 229940109529 pomegranate extract Drugs 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 description 52
- 231100000397 ulcer Toxicity 0.000 description 52
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 51
- 229960000381 omeprazole Drugs 0.000 description 51
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- 229940079593 drug Drugs 0.000 description 25
- 230000008485 antagonism Effects 0.000 description 21
- 238000000034 method Methods 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 230000001681 protective effect Effects 0.000 description 11
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 10
- 229960001138 acetylsalicylic acid Drugs 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 10
- 210000001187 pylorus Anatomy 0.000 description 9
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 6
- 230000001387 anti-histamine Effects 0.000 description 6
- 239000000739 antihistaminic agent Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000700199 Cavia porcellus Species 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000001771 impaired effect Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 4
- 229960001340 histamine Drugs 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 206010062065 Perforated ulcer Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 230000000767 anti-ulcer Effects 0.000 description 3
- 238000004299 exfoliation Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 239000003390 Chinese drug Substances 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 208000001649 Pica Diseases 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9064—Amomum, e.g. round cardamom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a Chinese medicinal composition for treating duodenal ulcer and a preparation method thereof. The composition consists of the following components in percentage by weight: 4 to 10 percent of coptis root extract, 4 to 11 percent of kudzu-vine root extract, 5 to 8 percent of astragalus extract, 5 to 11 percent of fig extract, 5 to 9 percent of trifoliate-orange immature fruit extract, 8 to 11 percent of pomegranate extract, 4 to 9 percent of common bletilla pseudobulb extract, 2 to 11 percent of fructus amomi extract, 8 to 12 percent of rangooncreeper fruit extract, 2 to 11 percent of officinal magnolia bark extract and one or more pharmaceutically acceptable additives/ carrying agents.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition of duodenal ulcer and method for preparing of said composition of treating.
Background technology
Past, many scientific principles were inquired into the occurrence cause about human ulcer.Take especially in some pressure or treatment rheumatic arthritis people such as on-steroidal anti-inflammatory drug all maybe with the substantial connection that has of ulcer, main because of in relatively too much gastric acid or duodenal acid solution are secreted.In fact can prevent the ulcer generation and cure it if can reduce the secretion of acid solution.
Others are then thought helicobacter pylori, and its normal (rod) can be present in stomach, because active mistake of carbamide can produce ammonia by force, therefore cause ulcer.If it exists in mucus and the mucosa constantly, can become the main reason of supervention ulcer.Being pursuant to this thinks if this bacillus that can neutralize then can prevent secondary ulcer to take place.
The present composition should not treated separately because have the independent use of proof can possess all advantages of the present invention.
Summary of the invention
Main purpose of the present invention is to provide a kind of Chinese medicine composition of treating duodenal ulcer.
Another object of the present invention is to provide the method for preparing said composition.
The present invention relates to treat the Chinese medicine composition of duodenal ulcer.Especially, the ulcer model that causes of the present invention's Chinese medicine composition that can treat duodenal ulcer ulcer model that can resist pylorus ligature law effectively and caused and histamine.The present invention also provides the preparation of compositions method.
Invention specifies
First purpose according to the present invention; A kind of Chinese medicine composition of treating duodenal ulcer is provided, and said composition is made up of the Rhizoma Coptidis of 4-10% weight ratio, the Radix Puerariae of 4-11% weight ratio, the Radix Astragali of 5-8% weight ratio, the Fructus Fici of 5-11% weight ratio, the Fructus Ponciri Trifoliatae (Fructus Ponciri Trifoliatae Immaturus) of 5-9% weight ratio, the Punica granatum L. of 8-11% weight ratio, the Pseudobulbus Bletillae (Rhizoma Bletillae) of 4-9% weight ratio, the Fructus Amomi of 2-11% weight ratio, the Fructus Quisqualis of 8-12% weight ratio and the Cortex Magnoliae Officinalis of 2-11% weight ratio.
Specifically, Chinese medicine composition of treating duodenal ulcer provided by the invention, said composition is by the Rhizoma Coptidis extract of 4-10% weight ratio and the Radix Puerariae extract of 4-11% weight ratio; The Radix Astragali extract of 5-8% weight ratio; The Fructus Fici extract of 5-11% weight ratio, the poncirus trifoliata extract of 5-9% weight ratio, the Punica granatum L. extract of 8-11% weight ratio; The Pseudobulbus Bletillae (Rhizoma Bletillae) extract of 4-9% weight ratio; The Fructus Amomi extract of 2-11% weight ratio, the Fructus Quisqualis extract of 8-12% weight ratio, and the Cortex Magnoliae Officinalis extract of 2-11% weight ratio and the acceptable additive of one or more pharmacy/supporting agent composition.
In instantiation of the present invention, its extract is a water extract.
In other instantiation of the present invention, the position that Rhizoma Coptidis and Radix Puerariae, the Radix Astragali are selected for use is the root of plant.In other instantiation of the present invention, the position that Fructus Fici, Fructus Ponciri Trifoliatae (Fructus Ponciri Trifoliatae Immaturus), Fructus Amomi and Fructus Quisqualis are selected for use is the fruit position of plant.
In other instantiation of the present invention, the position that Punica granatum L. is selected for use is the peel of plant.
In the more instantiations of the present invention, the position that Pseudobulbus Bletillae (Rhizoma Bletillae) is selected for use is the plant rhizome.
In other instantiation of the present invention, the position that Cortex Magnoliae Officinalis is selected for use is a plant bark.
Second purpose is to provide the method for preparing of the Chinese medicine composition that can treat duodenal ulcer according to the present invention.This method is to get above-mentioned medical material, extracts and processes after the acceptable additive/supporting agent of one or more pharmacy mixes through conventional method.
In other instantiation of the present invention, it is extracted as water and carries.
The form simple declaration
Table 1 represent omeprazole (as standard drug) and the cold constraint of Chinese medicine composition (HF) antagonism cause ulcer model (CRU).
Table 2 relatively omeprazole and the cold constraint of Chinese medicine composition (HF) antagonism cause the protective rate percentage ratio of ulcer model (CRU).
Table 3 gained be omeprazole and Chinese medicine composition (HF) antagonism aspirin cause the influence of ulcer model.
Table 4 gained be omeprazole and Chinese medicine composition (HF) antagonism aspirin cause the protective rate percentage ratio of ulcer model.
Table 5 gained be omeprazole and Chinese medicine composition (HF) antihistaminic is caused the influence of guinea pig duodenal ulcer.
Table 6 gained be omeprazole and Chinese medicine composition (HF) antihistaminic is caused the protective rate percentage ratio of guinea pig duodenal ulcer.
Table 7 gained be omeprazole and Chinese medicine composition (HF) antagonism ethanol cause the influence of ulcer.
Table 8 gained be omeprazole and Chinese medicine composition (HF) antagonism ethanol cause the protective rate percentage ratio of ulcer.
Table 9 gained by omeprazole and Chinese medicine composition (HF) antagonism pylorus ligation the influence of initiation ulcer.
Table 10 gained by omeprazole and Chinese medicine composition (HF) antagonism pylorus ligation the protective rate percentage ratio of initiation ulcer.
The compositions of table 11 gained is a Chinese medicine composition of the present invention.
Meeting of the present invention further according to testing graphic extension in addition, can provide other graphic mode in this experiment.Therefore should not limit any method goes to analyze the present invention.
Experiment flow:
Experiment in the body:
The applicant carries out multiple different situations and brings out the experiment of ulcer and inquire into Chinese medicine composition to the influence of this experiment and to be made into form following.Compare with Chinese medicine composition according to known anti-ulcer medicament omeprazole.
Experiment one: the influence of cold constraint ulcer (CRU) model
Method:
Bossed netted base prevented that feces from mixing (coprophagia), not water restriction to the fasting of six the every group about 150-175 grammes per square metres of body weight of one-tenth Mus in the cage in metabolic cage in 24 hours.Trial drug was thrown fixing animal and is given in preceding 45 minutes.Rat is fixed in the constraint cage and in 4 ℃ BOD culture environment, keeps two hours (the method is according to Senay and Levine 1967).After confinement time, rat is sacrificed at once and the abdominal cavity is cut, and takes out stomach and assists observation to obtain gastric injury by the tangent line curvature incision of the best at microscope (5X enlargement ratio).
Do classification with impaired according to severity and intensity according to special fixed score system
1. exfoliation=10
2. hemorrhage=20 of purple some property (frank)
3. ulcer=30 at a place or two places
4. more than ulcer=40 at two places
5. perforated ulcer=50
Which these damages appear at and all regard as the forward reaction of ulcer generation and can show the ratio that stomach is impaired.The performance of ulcer severity is called the ulcer index, means the impaired average mark of all rat stomach in the cohort.
The ulcer index definition is following:
UI (U.I.)=Us+Up * 10-1
This: the average mark of Us=ulcer severity
The percentage ratio of ulcer takes place in the Up=animal
The protection percentage calculation is following:
The percentage ratio of protection=(C-T/C) * 100
Here: the C=matched group shows that animal has the number of elements of ulcer reaction
T=receives the examination group to show that animal has the number of elements of ulcer reaction
Chinese medicine composition of the present invention after can be called " HF ", table 1 is listed in its influence that resists cold constraint ulcer model (CRU).The influence of standard drug omeprazole is also explained in table 1 back.
The protection percentage rate of Chinese medicine composition of the present invention (HF) and omeprazole antagonism CRU model are also in table 2 illustrated later.
Inference result: compositions of the present invention can effectively influence in CRU model.
Experiment two: aspirin causes the influence of duodenal ulcer model
Method: the method that aspirin causes duodenal ulcer is according to Djahanguiri (1969).Aspirin (150 milligrams/kg body weight) gives with the oral throwing of arabic gum float, handles giving the animal sacrifice in back 5 hours again and calculating UI and the protection index through aspirin.
Table 3 is listed in the duodenal ulcer influence that HF antagonism aspirin causes.The influence of standard drug omeprazole is also in table 3 illustrated later.The protection percentage rate of Chinese medicine composition of the present invention (HF) and this model of omeprazole antagonism are in table 4 illustrated later.
Inference result: Chinese medicine composition of the present invention can effectively resist aspirin and cause the duodenal ulcer model.
Experiment three: the influence of ulcer model causes in histamine
Method:
1. animal fasting 24 hours water restriction not.
2. throw in histamine and give last hour oral test medicine.
Histamine to throw and to give dosage be that 0.25 milligram/kg body weight i.m. gives seven times each 30 minutes at interval, and this can bring out guinea pig 100% duodenal ulcer (the method is according to Watt and Eagleton 1964).
4. inject at last that animal just gives the etherization sacrifice after 1.5 hours.
5. stomach pipettes out with duodenum and through cleaning, measures its damaged part.Calculate UI and protection index.
HF lists in table 5 to the influence that antihistaminic causes duodenal ulcer.The influence of standard drug omeprazole is also in table 5 illustrated later.The protection percentage rate of Chinese medicine composition of the present invention (HF) and omeprazole cause the duodenal ulcer model also in table six illustrated later to antihistaminic.
Inference result: Chinese medicine composition HF of the present invention shows effectively this ulcer model of antagonism.
Experiment four: ethanol causes the influence of duodenal ulcer model
1. become six the every group about 150-175 grammes per square metres of body weight of Mus fasting 24 hours, not water restriction.
2. trial drug is thrown to give throwing in preceding 45 minutes at ethanol and is given (oral).
3.1 rat (according to Wittertal) is given in the oral throwing of freezing solubility ethanol of milliliter
Through after 1 hour with Animal Anesthesia, and the abdominal cavity cut, take out stomach and obtain gastric injury along with the tangent line curvature incision of the best.
Gastric injury is measured with microscope (5X enlargement ratio) and is assisted to observe.
The alcohol damaged meeting of solubility presents the speckle that black damage clustering tool changes, and is parallel with the stomach main shaft usually.
5. impaired length is also summed up after measuring and is obtained an impaired gross score, calculates subsequently again and shows with percentage ratio.
Table 7 is listed in the ulcer influence that HF antagonism ethanol causes.The influence of standard drug omeprazole also is listed in table 7 illustrated later.The ulcer model that the protection percentage rate of Chinese medicine composition of the present invention (HF) and omeprazole antagonism ethanol cause also is listed in table 8 illustrated later.
Inference result: compositions of the present invention does not have and shows that effectively antagonism ethanol causes the ulcer model.
Experiment five: pylorus ligature law causes the influence of ulcer model
Method:
Animal fasting 24 hours in the metabolic cage that netted base is arranged to prevent that feces from mixing, water restriction not.
2. control rats feeding placebo, and experiment group was thrown in ligation and is given medicine out of the ordinary in preceding 45 minutes.
3. animal via anesthesia is cut the abdominal cavity at the xiphoid-process position, and gives ligation with stomach pylorus shifting out gently and prevent contiguous vascular injury (the method is according to people such as Shay 1945).
4. also supplying with drinking-water after rat being sewed up kept 4 hours.
5. the animal after 4 hours gives the etherization sacrifice with it and stomach is cut by the tangent line curvature of the best.
6. stomach gives the ulcer model of mark as other group through cleaning the back and counting the ulcer pointer.
Table 9 is listed in the ulcer influence that HF antagonism pylorus ligature law causes.Omeprazole also is listed in table 9 illustrated later as the influence of standard drug.The ulcer model that the protection percentage rate of Chinese medicine composition of the present invention (HF) and omeprazole antagonism pylorus ligature law cause is also listed in table 10 illustrated later.
Inference result: through comparing, Chinese medicine composition shows the very high antiulcer activity of tool, and Chinese medicine composition has better antiulcer activity than omeprazole.
Experiment six: the method for preparing of Chinese medicine composition
Method: carry out zooperal all Chinese medicines for purpose and need clean and clay into power again later.All Chinese medicines are obtained ratio and are shown in table 11.Also boiling and suitable concentration concentrates after adding entry for this reason.The Chinese medicine composition of standard drug and ratio are listed in table 11 illustrated later.The position that Chinese medicine is selected for use also will be mentioned.The preparation of placebo is designed to flavour, and abnormal smells from the patient and external form are similar to the Chinese medicine preparation that A Youfei reaches.
Table 1: Chinese medicine composition (HF) resists the influence that cold constraint causes ulcer model (CRU) with omeprazole (as standard drug)
In table, the 10=exfoliation; The purple some property of 20=is hemorrhage; 30=one place or two place's ulcer; , 40=is more than the ulcer at two places; The 50=perforated ulcer.
Table 2: the cold constraint of Chinese medicine composition (HF) and omeprazole (as standard drug) antagonism cause the protection percentage ratio of ulcer model (CRU)
| Group | Protection percentage ratio |
| Chinese medicine composition of the present invention (50 milligrams/kilogram) | 83.58 |
| Omeprazole (10 milligrams/kilogram) | 100％ |
It is 100% to learn other mixture protection ratio according to the protection ratio of omeprazole again as standard drug that the omeprazole protective rate is ordered.
Table 3: Chinese medicine composition (HF) and omeprazole (as standard drug) antagonism aspirin cause the influence of ulcer model (CRU)
In table, the 10=exfoliation; The purple some property of 20=is hemorrhage; 30=one place or two place's ulcer; 40=is more than the ulcer at two places; The 50=perforated ulcer.
Table 4: Chinese medicine composition (HF) and omeprazole (as standard drug) antagonism aspirin cause the protection percentage ratio of ulcer model (CRU)
| Group | Protection percentage ratio |
| Chinese medicine composition of the present invention (50 milligrams/kilogram) | 60.12 |
| Omeprazole (10 milligrams/kilogram) | 100％ |
It is 100% to learn other mixture protection ratio according to the protection ratio of omeprazole again as standard drug that the omeprazole protective rate is ordered.
Table 5: Chinese medicine composition (HF) and omeprazole (as standard drug) antihistaminic is brought out the influence of guinea pig duodenal ulcer model (CRU).
Table 6: Chinese medicine composition (HF) and omeprazole (as standard drug) bring out the protection percentage ratio of guinea pig duodenal ulcer to antihistaminic
| Mixture | Protection percentage ratio |
| Chinese medicine composition of the present invention | 93.07 |
| Omeprazole | 100％ |
It is 100% to learn other mixture protection ratio according to the protection ratio of omeprazole again as standard drug that the omeprazole protective rate is ordered.
Table 7: Chinese medicine composition (HF) and omeprazole (as standard drug) antagonism ethanol (ethanol) cause the influence of ulcer model.
| Mixture | Protection percentage ratio |
| The ethanol matched group | 73.5±1.5 |
| Chinese medicine composition of the present invention (100 milligrams of/kilogram p.o.)+ethanol | 69±7.0 |
| Omeprazole (100 milligrams of/kilogram p.o.)+ethanol | 56.0±9.12 |
Omeprazole as standard drug with its protective rate order into percentage hundred again according to the protection ratio of omeprazole mixture degree of protection than other.
Table 8: Chinese medicine composition (HF) resists the protection percentage rate that ethanol causes ulcer with omeprazole (as standard drug).
| Mixture | Protection percentage ratio |
| Chinese medicine composition | 25.71 |
| Omeprazole | 100.0 |
Omeprazole as standard drug with its protective rate order into percentage hundred again according to the protection ratio of omeprazole mixture degree of protection than other.
Table 9: Chinese medicine composition (HF) resists the influence that pylorus ligation causes the ulcer model with omeprazole (as standard drug).
| Mixture | The ulcer index | The protection index |
| The ligation matched group | 16.6 | 00 |
| Ligation+Chinese medicine is formed (50 milligrams of/kilogram p.o.)+ethanol | 4.2 | 65.89 |
| Ligation+omeprazole (10 milligrams of/kilogram p.o) | 6.6 | 51.44 |
Table 10: Chinese medicine composition (HF) resists the protection percentage ratio that pylorus ligation causes ulcer with omeprazole (as standard drug).
| Mixture | Protection percentage ratio % |
| Chinese medicine composition | 124.0 |
| Omeprazole | 100 |
Omeprazole as standard drug with its protective rate order into percentage hundred again according to the protection ratio of omeprazole mixture degree of protection than other.
Table 11: Chinese drug-treated group composition of the present invention
| Number | Composition title (use position) | ％ |
| 1 | The Radix Astragali (root) | 5-6％ |
| 2 | Fructus Fici (fruit) | 5-9％ |
| 3 | Rhizoma Coptidis (root) | 4-7％ |
| 4 | Radix Puerariae (root) | 4-8％ |
| 5 | Fructus Ponciri Trifoliatae (Fructus Ponciri Trifoliatae Immaturus) (fruit) | 5-8％ |
| 6 | Punica granatum L. (fruit) | 8-10％ |
| 7 | Pseudobulbus Bletillae (Rhizoma Bletillae) (rhizome) | 4-8％ |
| 8 | Fructus Amomi (fruit) | 2-9％ |
| 9 | Fructus Quisqualis (fruit) | 8-10％ |
| 10 | Cortex Magnoliae Officinalis (bark) | 2-9％ |
Claims (1)
1. Chinese medicine composition of treating duodenal ulcer, said composition is mixed and made into one or more pharmacy acceptable additive by the Cortex Magnoliae Officinalis of the Fructus Quisqualis of the Fructus Amomi of the Pseudobulbus Bletillae (Rhizoma Bletillae) of the Punica granatum L. of the Fructus Ponciri Trifoliatae (Fructus Ponciri Trifoliatae Immaturus) of the Fructus Fici of the Radix Astragali of the Radix Puerariae of the Rhizoma Coptidis of 4-10% weight ratio, 4-11% weight ratio, 5-8% weight ratio, 5-11% weight ratio, 5-9% weight ratio, 8-11% weight ratio, 4-9% weight ratio, 2-11% weight ratio, 8-12% weight ratio and 2-11% weight ratio back behind water extraction.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101430225A CN101810818B (en) | 2010-04-09 | 2010-04-09 | Chinese medicinal composition for treating duodenal ulcer and preparation method thereof |
| PCT/CN2010/000507 WO2011123996A1 (en) | 2010-04-09 | 2010-04-15 | Traditional chinese medicinal composition for curing duodenal ulcer and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101430225A CN101810818B (en) | 2010-04-09 | 2010-04-09 | Chinese medicinal composition for treating duodenal ulcer and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101810818A CN101810818A (en) | 2010-08-25 |
| CN101810818B true CN101810818B (en) | 2012-06-20 |
Family
ID=42618280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010101430225A Expired - Fee Related CN101810818B (en) | 2010-04-09 | 2010-04-09 | Chinese medicinal composition for treating duodenal ulcer and preparation method thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN101810818B (en) |
| WO (1) | WO2011123996A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102716341B (en) * | 2012-06-25 | 2013-10-23 | 胡玲玲 | Traditional Chinese medicinal composition for treating acute peptic ulcer bleeding and preparation method thereof |
| CN102920788A (en) * | 2012-11-16 | 2013-02-13 | 黑龙江中医药大学 | Preparation method of non-alkaloid pills extracted from fructus toosendan and rhizoma corydalis for treating gastric ulcer |
| CN109589385A (en) * | 2017-09-30 | 2019-04-09 | 张雷 | A kind of drug for treating constipation of old people |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101279072B (en) * | 2008-05-30 | 2010-12-22 | 连德峰 | Chinese medicine capsule for curing digestive system disease |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1110924A (en) * | 1994-04-28 | 1995-11-01 | 余慕良 | Effective drug for gastric disease |
| CN1076609C (en) * | 1996-06-13 | 2001-12-26 | 杨和华 | Shuweiping-drug for curing gastropathy |
| CN1067272C (en) * | 1998-12-02 | 2001-06-20 | 曾庆湘 | Powder for curing gastric ulcer |
| CN1425453A (en) * | 2003-01-20 | 2003-06-25 | 宋长贵 | Medicine for curing diseases of gastrointestinal system |
| CN1679840A (en) * | 2005-01-18 | 2005-10-12 | 郭继焕 | Medicine for treating gastroduodenal disease |
| CN1321680C (en) * | 2005-09-16 | 2007-06-20 | 王俊 | Chinese medicine composition for treating gastritis, gastric ulcer and duodenal ulcer |
| CN100355449C (en) * | 2005-10-31 | 2007-12-19 | 高庆刚 | Chinese medicine composition for treating stomach pain and preparing method thereof |
| CN1824167A (en) * | 2005-12-31 | 2006-08-30 | 闫自力 | Chinese medicinal composition for treating chronic gastritis and preparation method of medicinal tablet |
-
2010
- 2010-04-09 CN CN2010101430225A patent/CN101810818B/en not_active Expired - Fee Related
- 2010-04-15 WO PCT/CN2010/000507 patent/WO2011123996A1/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101279072B (en) * | 2008-05-30 | 2010-12-22 | 连德峰 | Chinese medicine capsule for curing digestive system disease |
Non-Patent Citations (3)
| Title |
|---|
| 娄兴德等.治疗胃、十二指肠溃疡病的临床经验.《长春中医学院学报》.2000,(第02期), * |
| 谭跃.中医药冶疗幽门螺旋菌相关性胃炎及消化性溃疡概况.《陕西中医》.1994,(第01期), * |
| 陈慈煦.胃与十二指肠溃疡病诊治体会.《贵阳中医学院学报》.1979,(第01期), * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011123996A1 (en) | 2011-10-13 |
| CN101810818A (en) | 2010-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Claeson et al. | Adhatoda vasica: a critical review of ethnopharmacological and toxicological data | |
| CN103463539B (en) | A kind of medicine for the treatment of eczema and its production and use | |
| CN102764339B (en) | Maca composition for improving sexual dysfunction and preparation method and application thereof | |
| CN101810818B (en) | Chinese medicinal composition for treating duodenal ulcer and preparation method thereof | |
| CN102895528B (en) | Traditional Chinese medicine for treatment of spleen/lung qi-deficiency type allergic rhinitis and preparation method thereof | |
| CN101810730B (en) | Chinese medicinal composition for treating gastric ulcer and preparation method thereof | |
| CN109223848A (en) | A kind of pharmaceutical composition and its preparation method and application for treating diarrhea | |
| CN102861193A (en) | Traditional Chinese medicine composition for treating gastric cancer | |
| CN111729033A (en) | Specific traditional Chinese medicine stomach-protecting powder for preventing stomach cancer | |
| CN103623065B (en) | Medicine composition for treating influenza | |
| CN113769013A (en) | Traditional Chinese medicine stomach-protecting powder for preventing stomach cancer | |
| CN105596989A (en) | Medicine for treating rheumatism and rheumatoid disease | |
| CN100446789C (en) | Traditional Chinese medicine pill for clearing toxin of pneumonia | |
| EP1358887B1 (en) | Composition of traditional chinese medicines for preventing and treating cerebrovascular disease | |
| CN1857708A (en) | Chinese medicine preparation for treating cavitative gastric ulcer | |
| CN103585471B (en) | Traditional Chinese medicine composition for treating thrombocytopenia | |
| CN113855770A (en) | Traditional Chinese medicine composition for treating reflux esophagitis and preparation method thereof | |
| US6855347B2 (en) | Composition for treating gastric ulcer and a process for preparing the same | |
| CN101637527A (en) | Application method of amur cork for preparing digestive ulcer medicament | |
| CN102846848B (en) | Traditional Chinese medicine preparation for ovarian stimulation and preparation technology thereof | |
| CN106310122A (en) | Traditional Chinese medicine composition for treating chronic gastritis as well as capsules and preparation method of traditional Chinese medicine composition | |
| CA2480223C (en) | A composition for treating gastric ulcer and a process for preparing the same | |
| CN115998817A (en) | Traditional Chinese medicine stomach-protecting powder for preventing stomach cancer | |
| CN101002897A (en) | Medicine for treating proganital lichen sclerosus disease | |
| Van Anh et al. | 9. Gastroprotective effect of Vien Khoi Tim capsules on indomethacin-induced gastric ulcers in rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: BEIJING SHUISHENGMU TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: TONGLING RESTORATION INVESTMENT CONSULTING CO., LTD. Effective date: 20120412 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 244000 TONGLING, ANHUI PROVINCE TO: 100098 HAIDIAN, BEIJING |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20120412 Address after: 100098 Lou Huajie building, No. 13, Big Bell Temple, Beijing, Haidian District, B215 Applicant after: BEIJING SHUISHENGMU TECHNOLOGY Co.,Ltd. Address before: 244000, Anhui village, south section of Huaihe Avenue, Tongling, 18 Applicant before: Tongling Weixin Investment & Consulting Co.,Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CI01 | Publication of corrected invention patent application |
Correction item: Patentee Correct: Beijing ShuishengmuTechnology Co., Ltd.|100098 Lou Huajie building, No. 13, Big Bell Temple, Beijing, Haidian District, B215 False: Beijing Shuishengmu Technology Co., Ltd.|100098 Lou Huajie building, No. 13, Big Bell Temple, Beijing, Haidian District, B215 Number: 21 Volume: 28 |
|
| ERR | Gazette correction | ||
| ASS | Succession or assignment of patent right |
Owner name: GCA PHARMACEUTICAL COMPANY Free format text: FORMER OWNER: BEIJING SHUISHENGMU TECHNOLOGY CO., LTD. Effective date: 20121213 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20121213 Address after: New Jersey, Jersey City, USA Patentee after: GCA pharmaceuticals Address before: 100098 Lou Huajie building, No. 13, Big Bell Temple, Beijing, Haidian District, B215 Patentee before: Beijing Water Sacred Wood Technology Co.,Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120620 Termination date: 20150409 |
|
| EXPY | Termination of patent right or utility model |